BR112018005208A2 - Compostos heterocíclicos que contêm benzilamina e composições úteis contra infecção micobacteriana - Google Patents
Compostos heterocíclicos que contêm benzilamina e composições úteis contra infecção micobacterianaInfo
- Publication number
- BR112018005208A2 BR112018005208A2 BR112018005208A BR112018005208A BR112018005208A2 BR 112018005208 A2 BR112018005208 A2 BR 112018005208A2 BR 112018005208 A BR112018005208 A BR 112018005208A BR 112018005208 A BR112018005208 A BR 112018005208A BR 112018005208 A2 BR112018005208 A2 BR 112018005208A2
- Authority
- BR
- Brazil
- Prior art keywords
- compounds containing
- heterocyclic compounds
- compositions useful
- mycobacterial infection
- useful against
- Prior art date
Links
- WGQKYBSKWIADBV-UHFFFAOYSA-N benzylamine Chemical compound NCC1=CC=CC=C1 WGQKYBSKWIADBV-UHFFFAOYSA-N 0.000 title 2
- 206010062207 Mycobacterial infection Diseases 0.000 title 1
- 150000002391 heterocyclic compounds Chemical class 0.000 title 1
- 239000000203 mixture Substances 0.000 title 1
- 208000027531 mycobacterial infectious disease Diseases 0.000 title 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
- C07D471/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
- C07D471/04—Ortho-condensed systems
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
- A61K31/4164—1,3-Diazoles
- A61K31/4188—1,3-Diazoles condensed with other heterocyclic ring systems, e.g. biotin, sorbinil
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
- A61K31/425—Thiazoles
- A61K31/429—Thiazoles condensed with heterocyclic ring systems
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/4353—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems
- A61K31/437—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems the heterocyclic ring system containing a five-membered ring having nitrogen as a ring hetero atom, e.g. indolizine, beta-carboline
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/04—Anorexiants; Antiobesity agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
- A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/04—Antibacterial agents
- A61P31/06—Antibacterial agents for tuberculosis
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D513/00—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for in groups C07D463/00, C07D477/00 or C07D499/00 - C07D507/00
- C07D513/02—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for in groups C07D463/00, C07D477/00 or C07D499/00 - C07D507/00 in which the condensed system contains two hetero rings
- C07D513/04—Ortho-condensed systems
Landscapes
- Chemical & Material Sciences (AREA)
- Health & Medical Sciences (AREA)
- Organic Chemistry (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Life Sciences & Earth Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Epidemiology (AREA)
- Diabetes (AREA)
- Oncology (AREA)
- Communicable Diseases (AREA)
- Obesity (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Hematology (AREA)
- Pulmonology (AREA)
- Emergency Medicine (AREA)
- Endocrinology (AREA)
- Child & Adolescent Psychology (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Nitrogen Condensed Heterocyclic Rings (AREA)
- Nitrogen And Oxygen Or Sulfur-Condensed Heterocyclic Ring Systems (AREA)
Applications Claiming Priority (3)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US201562220192P | 2015-09-17 | 2015-09-17 | |
US62/220,192 | 2015-09-17 | ||
PCT/US2016/052558 WO2017049321A1 (en) | 2015-09-17 | 2016-09-19 | Benzyl amine-containing heterocyclic compounds and compositions useful against mycobacterial infection |
Publications (2)
Publication Number | Publication Date |
---|---|
BR112018005208A2 true BR112018005208A2 (pt) | 2018-10-02 |
BR112018005208B1 BR112018005208B1 (pt) | 2023-12-12 |
Family
ID=58289763
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
BR112018005208-6A BR112018005208B1 (pt) | 2015-09-17 | 2016-09-19 | Compostos heterocíclicos que contêm benzilamina e composições úteis contra infecção micobacteriana |
Country Status (15)
Country | Link |
---|---|
US (2) | US10919888B2 (pt) |
EP (1) | EP3328382A4 (pt) |
JP (1) | JP7055378B2 (pt) |
KR (1) | KR20180053386A (pt) |
CN (1) | CN108348510B (pt) |
AU (2) | AU2016324598A1 (pt) |
BR (1) | BR112018005208B1 (pt) |
CA (1) | CA2998375A1 (pt) |
CL (1) | CL2018000688A1 (pt) |
HK (1) | HK1252225A1 (pt) |
IL (1) | IL257743B (pt) |
MX (2) | MX2018003294A (pt) |
PE (1) | PE20181352A1 (pt) |
WO (1) | WO2017049321A1 (pt) |
ZA (1) | ZA201802323B (pt) |
Families Citing this family (10)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
WO2017049321A1 (en) | 2015-09-17 | 2017-03-23 | Miller Marvin J | Benzyl amine-containing heterocyclic compounds and compositions useful against mycobacterial infection |
US10858359B2 (en) | 2016-06-07 | 2020-12-08 | Jacobio Pharmaceuticals Co., Ltd. | Heterocyclic ring derivatives useful as SHP2 inhibitors |
SG11201908820VA (en) | 2017-03-23 | 2019-10-30 | Jacobio Pharmaceuticals Co Ltd | Novel heterocyclic derivatives useful as shp2 inhibitors |
CN108159049B (zh) * | 2018-02-01 | 2021-01-05 | 中国科学院广州生物医药与健康研究院 | 一种吡啶类化合物的新用途 |
EP3976031A4 (en) * | 2019-05-28 | 2023-07-12 | Shionogi & Co., Ltd | MEDICATION FOR THE TREATMENT OF MYCOBACTERIAL INFECTION IN THE FORM OF A COMBINATION OF A CYTOCHROME BC1 INHIBITOR WITH CLARITHROMYCIN OR AZITHROMYCIN AND CLOFAZIMIN |
TW202124379A (zh) * | 2019-09-10 | 2021-07-01 | 日商鹽野義製藥股份有限公司 | 對分枝桿菌感染有用之含苄胺的5,6-雜芳族化合物 |
MX2022003037A (es) * | 2019-09-13 | 2022-04-07 | Janssen Sciences Ireland Unlimited Co | Compuestos antibacterianos. |
AU2020356630A1 (en) * | 2019-09-26 | 2022-03-31 | The Global Alliance For Tb Drug Development, Inc. | Thiazole carboxamide compounds and use thereof for the treatment of mycobacterial infections |
WO2022119899A1 (en) * | 2020-12-02 | 2022-06-09 | Shionogi & Co., Ltd. | A medicament for treating mycobacterial infection characterized by combining a cytochrome bc1 inhibitor with clarithromycin or azithromycin |
CN117396475A (zh) * | 2021-03-16 | 2024-01-12 | 爱尔兰詹森科学公司 | 抗菌化合物 |
Family Cites Families (78)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
FR2525602A1 (fr) | 1982-04-21 | 1983-10-28 | Synthelabo | Imidazo(1,2-a)pyridines, leur preparation et leur application en therapeutique |
FR2593818B1 (fr) | 1986-02-05 | 1988-04-29 | Synthelabo | Derives d'acylaminomethyl-3 imidazo(1,2-a)pyridine, leur preparation et leur application en therapeutique |
DE4010797A1 (de) | 1990-04-04 | 1991-10-10 | Hoechst Ag | Substituierte azole, verfahren zu deren herstellung, diese enthaltende mittel und deren verwendung |
DE4023215A1 (de) | 1990-07-21 | 1992-01-23 | Hoechst Ag | Substituierte azole, verfahren zu deren herstellung, sie enthaltende mittel und deren verwendung |
JPH0539205A (ja) | 1990-12-21 | 1993-02-19 | Takeda Chem Ind Ltd | 農園芸用混合組成物 |
JP3026845B2 (ja) | 1991-02-20 | 2000-03-27 | 日清製粉株式会社 | ピペリジン誘導体 |
US5464843A (en) | 1992-06-23 | 1995-11-07 | G.D. Searle & Co. | Imidazo[1,2-a]pyridinyldiacid compounds for cognitive enhancement and for treatment of cognitive disorders and neutrotoxic injury |
US5721273A (en) | 1993-12-15 | 1998-02-24 | Alcon Laboratories, Inc. | Use of certain 9-halo-13,14-dihydroprostaglandins to treat glaucoma and ocular hypertension |
WO1995028389A1 (fr) | 1994-04-15 | 1995-10-26 | Yamanouchi Pharmaceutical Co., Ltd. | Compose spiro et composition medicinale issue de ce compose |
AU2935895A (en) | 1994-07-15 | 1996-02-16 | Takeda Chemical Industries Ltd. | Tricyclic compounds, their production and use |
US6323227B1 (en) | 1996-01-02 | 2001-11-27 | Aventis Pharmaceuticals Products Inc. | Substituted N-[(aminoiminomethyl or aminomethyl)phenyl]propyl amides |
US6080767A (en) | 1996-01-02 | 2000-06-27 | Aventis Pharmaceuticals Products Inc. | Substituted n-[(aminoiminomethyl or aminomethyl)phenyl]propyl amides |
JPH09249666A (ja) | 1996-01-12 | 1997-09-22 | Takeda Chem Ind Ltd | 三環性化合物の製造法およびその中間体 |
AU8096798A (en) | 1997-06-27 | 1999-01-19 | Resolution Pharmaceuticals Inc. | Dopamine d4 receptor ligands |
AUPP278498A0 (en) | 1998-04-03 | 1998-04-30 | Australian Nuclear Science & Technology Organisation | Peripheral benzodiazepine receptor binding agents |
EP1085846A2 (en) | 1998-06-08 | 2001-03-28 | Advanced Medicine, Inc. | Multibinding inhibitors of microsomal triglyceride transferase protein |
GB2351081A (en) | 1999-06-18 | 2000-12-20 | Lilly Forschung Gmbh | Pharmaceutically active imidazoline compounds and analogues thereof |
IL148698A0 (en) | 1999-09-17 | 2002-09-12 | Cor Therapeutics Inc | INHIBITORS OF FACTOR Xa |
US6632815B2 (en) | 1999-09-17 | 2003-10-14 | Millennium Pharmaceuticals, Inc. | Inhibitors of factor Xa |
US6403588B1 (en) | 2000-04-27 | 2002-06-11 | Yamanouchi Pharmaceutical Co., Ltd. | Imidazopyridine derivatives |
DK1277754T3 (da) | 2000-04-27 | 2005-11-14 | Astellas Pharma Inc | Imidazopyridinderivater |
AU2001270297A1 (en) | 2000-06-30 | 2002-01-14 | Neurogen Corporation | 2-phenylimidazo(1,2-a)pyridine derivatives: a new class of gaba brain receptor ligands |
GB0021670D0 (en) | 2000-09-04 | 2000-10-18 | Astrazeneca Ab | Chemical compounds |
DE10247269A1 (de) | 2002-10-10 | 2004-04-22 | Grünenthal GmbH | Substituierte C-Imidazo[1,2-a]pyridin-3-yl-methylamine |
AU2003299791A1 (en) | 2002-12-20 | 2004-07-22 | Bayer Pharmaceuticals Corporation | Substituted 3,5-dihydro-4h-imidazol-4-ones for the treatment of obesity |
WO2004100868A2 (en) | 2003-04-23 | 2004-11-25 | Abbott Laboratories | Method of treating transplant rejection |
US20050113576A1 (en) | 2003-08-05 | 2005-05-26 | Chih-Hung Lee | Fused azabicyclic compounds that inhibit vanilloid receptor subtype 1 (VR1) receptor |
KR100807920B1 (ko) | 2003-12-23 | 2008-02-27 | 화이자 인코포레이티드 | 신규한 퀴놀린 유도체 |
US7566781B2 (en) | 2004-05-10 | 2009-07-28 | Banyu Pharmaceutical Co., Ltd. | Imidazopyridine compound |
US20060084806A1 (en) | 2004-07-21 | 2006-04-20 | Ramasubramanian Sridharan | Processes for the preparation of imidazo[1,2-a] pyridine derivatives |
WO2006015737A1 (de) | 2004-08-02 | 2006-02-16 | Schwarz Pharma Ag | Carboxamide des indolizins und seiner aza- und diazaderivate |
KR20070084026A (ko) | 2004-11-11 | 2007-08-24 | 페레르 인터내쇼날 에스.에이. | 이미다조[1,2-a]피리딘 화합물, 조성물, 이들과 관련된용도 및 제조 방법 |
DE102005016547A1 (de) * | 2005-04-08 | 2006-10-12 | Grünenthal GmbH | Substituierte 5,6,7,8-Tetrahydro-imidazo(1,2-a)pyridin-2-ylamin-Verbindungen und deren Verwendung zur Herstellung von Arzneimitteln |
WO2007015866A2 (en) | 2005-07-20 | 2007-02-08 | Kalypsys, Inc. | Inhibitors of p38 kinase and methods of treating inflammatory disorders |
RU2008101923A (ru) | 2005-08-05 | 2009-09-10 | Астразенека Аб (Se) | Трициклические бензимидазолы и их применение в качестве модуляторов метаботропного глутаматного рецептора |
WO2007136607A2 (en) | 2006-05-18 | 2007-11-29 | Merck & Co., Inc. | Substituted esters as cannabinoid-1 receptor modulators |
JP2010504957A (ja) | 2006-09-29 | 2010-02-18 | アクテリオン ファーマシューティカルズ リミテッド | 3−アザ−ビシクロ[3.1.0]ヘキサン誘導体 |
US7790741B2 (en) | 2006-10-06 | 2010-09-07 | Abbott Laboratories | Imidazothiazoles and imidazoxazoles |
AU2007334519A1 (en) | 2006-12-14 | 2008-06-26 | Merck Sharp & Dohme Corp. | Acyl bipiperidinyl compounds, compositions containing such compounds and methods of treatment |
EP2134713A2 (en) | 2006-12-20 | 2009-12-23 | Schering Corporation | Novel jnk inhibitors |
CA2680173A1 (en) | 2007-03-07 | 2008-09-12 | Alantos Pharmaceuticals Holding, Inc. | Metalloprotease inhibitors containing a heterocyclic moiety |
EP1980251A1 (en) | 2007-04-13 | 2008-10-15 | Glaxo Group Limited | Pyrrolo[3,2,1-ij]quinoline-4-one derivatives for treating tuberculosis |
CL2008001631A1 (es) | 2007-06-06 | 2009-01-02 | Smithkline Beecham Corp | Compuestos derivados de heterociclos sustituidos, con la presencia de un grupo fenoxi, inhibidores de transcriptasa inversa; composicion farmaceutica; y uso en el tratamiento de infecciones virales por vih. |
EP2200440B1 (en) | 2007-07-23 | 2017-07-19 | Crestone, Inc. | Antibacterial amide and sulfonamide substituted heterocyclic urea compounds |
EP2219646A4 (en) | 2007-12-21 | 2010-12-22 | Univ Rochester | METHOD FOR MODIFYING THE LIFETIME OF EUKARYOTIC ORGANISMS |
BRPI0912029A2 (pt) | 2008-02-01 | 2020-06-30 | Orchid Research Laboratories Limited | novos heterociclos |
CA2724842A1 (en) | 2008-05-19 | 2009-11-26 | Sunovion Pharmaceuticals Inc. | Imidazo[1,2-a]pyridine compounds |
WO2009148961A2 (en) | 2008-05-29 | 2009-12-10 | Wisconsin Alumni Research Foundation | Drugs to prevent hpv infection |
JP5536773B2 (ja) | 2008-08-14 | 2014-07-02 | ベータ・ファーマ・カナダ・インコーポレイテッド | Ep4受容体アンタゴニストとしてのヘテロ環式アミド誘導体 |
US8293909B2 (en) | 2008-09-11 | 2012-10-23 | Bristol-Myers Squibb Company | Compounds for the treatment of hepatitis C |
US8198449B2 (en) | 2008-09-11 | 2012-06-12 | Bristol-Myers Squibb Company | Compounds for the treatment of hepatitis C |
JP2012510983A (ja) | 2008-12-04 | 2012-05-17 | プロキシマジェン エルティーディー | イミダゾピリジン化合物 |
US20110301143A1 (en) | 2009-02-23 | 2011-12-08 | Elise Isabel | Heterocyclic derivatives as inhibitors of stearoyl-coenzyme a delta-9 desaturase |
EP2401275B1 (en) | 2009-02-24 | 2013-07-24 | Respiratorius AB | Naphthyridine derivatives having bronchodilating activity |
NZ598294A (en) | 2009-09-03 | 2013-07-26 | Bioenergenix | Heterocyclic compounds for the inhibition of pask |
WO2011050245A1 (en) | 2009-10-23 | 2011-04-28 | Yangbo Feng | Bicyclic heteroaryls as kinase inhibitors |
EP2496578A4 (en) | 2009-11-05 | 2013-08-21 | Univ Notre Dame Du Lac | IMIDAZO [1,2-A] PYRIDINE COMPOUNDS, THEIR SYNTHESIS AND METHODS OF USE THEREOF |
SG184073A1 (en) | 2010-03-18 | 2012-10-30 | Pasteur Institut Korea | Anti-infective compounds |
UA109803C2 (xx) | 2011-02-25 | 2015-10-12 | (ПІРИДИН-4-ІЛ)БЕНЗИЛАМІДИ ЯК АЛОСТЕРИЧНІ МОДУЛЯТОРИ АЛЬФА-7 nAChR | |
KR20140093610A (ko) * | 2011-04-21 | 2014-07-28 | 재단법인 한국파스퇴르연구소 | 소염 화합물 |
KR20140040774A (ko) | 2011-05-30 | 2014-04-03 | 아스테라스 세이야쿠 가부시키가이샤 | 이미다조피리딘 화합물 |
BR112014010368A2 (pt) * | 2011-10-31 | 2017-04-25 | Xenon Pharmaceuticals Inc | biaril éter sulfonamidas e seu uso como agentes terapêuticos |
WO2013122897A1 (en) | 2012-02-13 | 2013-08-22 | Amgen Inc. | Dihydrobenzoxazine and tetrahydroquinoxaline sodium channel inhibitors |
RU2696278C2 (ru) * | 2012-07-18 | 2019-08-01 | Юниверсити Оф Нотр Дам Дю Лак | 5,5-гетероароматические противоинфекционные соединения |
RS57779B1 (sr) | 2012-11-20 | 2018-12-31 | Merial Inc | Antihelmintska jedinjenja i kompozicije i postupak za njihovu upotrebu |
JP6056872B2 (ja) * | 2012-11-30 | 2017-01-11 | アステラス製薬株式会社 | イミダゾピリジン化合物 |
WO2015014993A2 (en) * | 2013-08-02 | 2015-02-05 | Institut Pasteur Korea | Anti-infective compounds |
CN105524058B (zh) | 2014-10-21 | 2018-03-27 | 广州艾格生物科技有限公司 | 吡唑并[1,5‑a]吡啶类化合物及其应用 |
LT3316969T (lt) | 2015-07-02 | 2022-03-25 | Janssen Sciences Ireland Unlimited Company | Antibakteriniai junginiai |
WO2017049321A1 (en) | 2015-09-17 | 2017-03-23 | Miller Marvin J | Benzyl amine-containing heterocyclic compounds and compositions useful against mycobacterial infection |
MA45375A (fr) | 2016-06-16 | 2019-04-24 | Janssen Sciences Ireland Unlimited Co | Composés hétérocycliques utilisés en tant qu'agents antibacteriens |
KR20190017948A (ko) | 2016-06-16 | 2019-02-20 | 얀센 사이언시즈 아일랜드 언리미티드 컴퍼니 | 항균제로서의 헤테로고리 화합물 |
EP3266454A1 (en) | 2016-07-07 | 2018-01-10 | Forschungszentrum Borstel Leibniz-Zentrum für Medizin und Biowissenschaften | Acc inhibitors for use in treating mycobacterial diseases |
KR20190121315A (ko) | 2017-03-01 | 2019-10-25 | 얀센 사이언시즈 아일랜드 언리미티드 컴퍼니 | 병용 요법 |
CN108159049B (zh) | 2018-02-01 | 2021-01-05 | 中国科学院广州生物医药与健康研究院 | 一种吡啶类化合物的新用途 |
US20210009583A1 (en) | 2018-03-12 | 2021-01-14 | University Of Notre Dame Du Lac | Deuterated imidazopyridines |
CN108358917B (zh) | 2018-04-24 | 2020-06-19 | 北京市结核病胸部肿瘤研究所 | 含有碱性稠环片段的咪唑并[1,2-a]吡啶-3-酰胺类化合物及其制备方法 |
MX2022003037A (es) | 2019-09-13 | 2022-04-07 | Janssen Sciences Ireland Unlimited Co | Compuestos antibacterianos. |
-
2016
- 2016-09-19 WO PCT/US2016/052558 patent/WO2017049321A1/en active Application Filing
- 2016-09-19 CA CA2998375A patent/CA2998375A1/en active Pending
- 2016-09-19 US US15/760,939 patent/US10919888B2/en active Active
- 2016-09-19 MX MX2018003294A patent/MX2018003294A/es unknown
- 2016-09-19 KR KR1020187010743A patent/KR20180053386A/ko not_active Application Discontinuation
- 2016-09-19 IL IL257743A patent/IL257743B/en unknown
- 2016-09-19 CN CN201680063042.7A patent/CN108348510B/zh active Active
- 2016-09-19 BR BR112018005208-6A patent/BR112018005208B1/pt active IP Right Grant
- 2016-09-19 AU AU2016324598A patent/AU2016324598A1/en not_active Abandoned
- 2016-09-19 JP JP2018514425A patent/JP7055378B2/ja active Active
- 2016-09-19 PE PE2018000402A patent/PE20181352A1/es unknown
- 2016-09-19 EP EP16847573.9A patent/EP3328382A4/en not_active Withdrawn
-
2018
- 2018-03-15 CL CL2018000688A patent/CL2018000688A1/es unknown
- 2018-03-15 MX MX2021000189A patent/MX2021000189A/es unknown
- 2018-04-10 ZA ZA2018/02323A patent/ZA201802323B/en unknown
- 2018-09-06 HK HK18111462.6A patent/HK1252225A1/zh unknown
-
2020
- 2020-12-28 US US17/135,927 patent/US11820767B2/en active Active
-
2021
- 2021-06-14 AU AU2021203931A patent/AU2021203931A1/en not_active Abandoned
Also Published As
Publication number | Publication date |
---|---|
CN108348510A (zh) | 2018-07-31 |
CL2018000688A1 (es) | 2018-11-16 |
EP3328382A1 (en) | 2018-06-06 |
ZA201802323B (en) | 2019-01-30 |
KR20180053386A (ko) | 2018-05-21 |
AU2021203931A1 (en) | 2021-07-08 |
CA2998375A1 (en) | 2017-03-23 |
BR112018005208B1 (pt) | 2023-12-12 |
PE20181352A1 (es) | 2018-08-22 |
RU2018111768A (ru) | 2019-10-17 |
MX2021000189A (es) | 2021-03-25 |
MX2018003294A (es) | 2019-04-25 |
EP3328382A4 (en) | 2018-12-19 |
IL257743B (en) | 2022-08-01 |
HK1252225A1 (zh) | 2019-05-24 |
AU2016324598A1 (en) | 2018-03-15 |
CN108348510B (zh) | 2022-01-04 |
US20210198254A1 (en) | 2021-07-01 |
JP7055378B2 (ja) | 2022-04-18 |
JP2018532723A (ja) | 2018-11-08 |
WO2017049321A1 (en) | 2017-03-23 |
US10919888B2 (en) | 2021-02-16 |
RU2018111768A3 (pt) | 2020-02-20 |
US11820767B2 (en) | 2023-11-21 |
US20180265506A1 (en) | 2018-09-20 |
IL257743A (en) | 2018-04-30 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
BR112018005208A2 (pt) | Compostos heterocíclicos que contêm benzilamina e composições úteis contra infecção micobacteriana | |
DK3495023T3 (da) | Semifluorerede forbindelser og sammensætninger deraf | |
BR112017000039A2 (pt) | composições agrícolas e aplicações que utilizam óleos essenciais | |
DK3892302T3 (da) | Sammensætninger indeholdende ibrutinib | |
DK3102555T3 (da) | Sammensætninger af forbindelser og anvendelser deraf | |
KR20180084891A (ko) | 구조 조성물 및 방법 | |
DK3182962T3 (da) | Compositions and uses of amidine derivatives | |
DK3359241T3 (da) | Formuleringer af pthrp-analoger, transdermale plastre deraf og anvendelser deraf | |
DK3416996T3 (da) | Hærdelig sammensætning | |
MA41794A (fr) | Agents thérapeutiques modifiés et compositions associées | |
BR112017016465A2 (pt) | composto heterocíclico e composição farmacêutica que o compreende | |
DK3081263T3 (da) | Sammensætninger og redskaber til behandling af glaukom | |
DK3200748T3 (da) | Sammensætninger og fremgangsmåder til behandling og profylakse af infektioner på operationssted | |
DK3288379T3 (da) | Peptidsammensætninger og anvendelsesmåder | |
DK3083683T3 (da) | Sammensætninger og fremgangsmåder til behandling af fedtvævsansamlinger | |
DK2777689T3 (da) | Ny farmaceutisk sammensætning til behandling af svampeinfektioner | |
EP3237413A4 (en) | Compositions of fatostatin based heterocyclic compounds and uses thereof | |
DK3261609T3 (da) | Sammensætninger omfattende ravsyre og akonitsyre | |
IL271550B (en) | A cyclic coumarin-like compound as a mek inhibitor and its use | |
DK3411008T3 (da) | Sammensætninger omfattende aktive solbeskyttelsesmidler med polyhydroxyfulleren | |
MA43166A (fr) | Formulation de fviii | |
DK3179858T3 (da) | Forme og sammensætninger af en ERK-inhibitor | |
DK3436029T3 (da) | Forbindelse indeholdende dexpanthenolglycosid | |
KR20180084930A (ko) | 접착제 조성물 및 구조체 | |
DK3171873T3 (da) | Sammensætning omfattende en ester af alfa-tocopherol til forebyggelse og behandling af allergisk rhinitis |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
B07D | Technical examination (opinion) related to article 229 of industrial property law [chapter 7.4 patent gazette] |
Free format text: DE ACORDO COM O ARTIGO 229-C DA LEI NO 10196/2001, QUE MODIFICOU A LEI NO 9279/96, A CONCESSAO DA PATENTE ESTA CONDICIONADA A ANUENCIA PREVIA DA ANVISA. CONSIDERANDO A APROVACAO DOS TERMOS DO PARECER NO 337/PGF/EA/2010, BEM COMO A PORTARIA INTERMINISTERIAL NO 1065 DE 24/05/2012, ENCAMINHA-SE O PRESENTE PEDIDO PARA AS PROVIDENCIAS CABIVEIS. |
|
B07E | Notification of approval relating to section 229 industrial property law [chapter 7.5 patent gazette] | ||
B06U | Preliminary requirement: requests with searches performed by other patent offices: procedure suspended [chapter 6.21 patent gazette] | ||
B07A | Application suspended after technical examination (opinion) [chapter 7.1 patent gazette] | ||
B09A | Decision: intention to grant [chapter 9.1 patent gazette] | ||
B16A | Patent or certificate of addition of invention granted [chapter 16.1 patent gazette] |
Free format text: PRAZO DE VALIDADE: 20 (VINTE) ANOS CONTADOS A PARTIR DE 19/09/2016, OBSERVADAS AS CONDICOES LEGAIS |